Who Paid My Doc
Linda Wolbers
Pain Medicine Capitola, CA Medical Doctor
NPI 1093753899 CMS profile 186000
4400 Capitola Rd Ste 200, Ste 11, Capitola, CA 95010
General payments
$2,724
Research payments
$151
Ownership & investment interest
$0
Research they led as principal investigator
$69,576
Through program year 2025, Linda Wolbers of Capitola, CA is reported in the CMS Open Payments database as having received $2,724 across 82 general payments and $151 in research payments paid to them. Separately, studies naming them as principal investigator received $69,576 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 53rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $219 | 2 | |
| 2024 | General | $632 | 6 | |
| 2023 | General | $422 | 3 | |
| 2022 | General | $72 | 4 | |
| 2021 | General | $219 | 10 | |
| 2020 | General | $468 | 21 | |
| 2020 | Research | $81 | 1 | |
| 2019 | General | $692 | 36 | |
| 2019 | Research | $70 | 1 |
Beside peers
- Linda Wolbers
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Linda Wolbers were reported at $219. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.
Show as a table
| Year | Linda Wolbers | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $692 | $506 | $144–$1,566 | $163 |
| 2020 | $468 | $315 | $96–$934 | $114 |
| 2021 | $219 | $452 | $134–$1,237 | $132 |
| 2022 | $72 | $475 | $124–$1,407 | $149 |
| 2023 | $422 | $480 | $136–$1,384 | $160 |
| 2024 | $632 | $521 | $164–$1,511 | $164 |
| 2025 | $219 | $470 | $146–$1,462 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 30 drugsPart D claims
1,113
Drug cost
$212,010
Branded share of claims
24.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Levorphanol Tartrate | Generic | 61 | $173,004 | |
| Xtampza Er Oxycodone Myristate | Brand | 13 | $8,677 | |
| Oxycontin Oxycodone Hcl | Brand | 13 | $5,715 | |
| Buprenorphine | Generic | 19 | $4,179 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 155 | $4,039 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 67 | $2,838 | |
| Oxycodone Hcl | Generic | 96 | $2,490 | |
| Fentanyl | Generic | 13 | $1,974 | |
| Gabapentin | Generic | 105 | $1,474 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 26 | $815 |
The 10 drugs with the highest cost, of 30 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$23,367
Medicare patients
52
Services billed
521
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 65% | |
| Depression | 35% | |
| Diabetes | 27% | |
| Chronic kidney disease | 25% | |
| Osteoporosis | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
84 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Pain Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.